Literature DB >> 29459996

Robotic surgery in public hospitals of Latin-America: a castle of sand?

Fernando P Secin1, Rafael Coelho2, Juan I Monzó Gardiner3, Jose Gadú Campos Salcedo4, Roberto Puente5, Levin Martínez6, Diana Finkelstein3, Rair Valero7, Antonio León7, Daniel Angeloni8, José Rozanec9, Milton Berger10, Leandro Totti Cavazzola11, Eliney Ferreira Faria12, Roberto Días Machado12, Felipe Lott13, Franz Campos13, Jorge G Morales Montor14, Carlos Sánchez Moreno15, Hugo Dávila Barrios7.   

Abstract

INTRODUCTION: There is no information about the evolution of robotic programs in public hospitals of Latin-America.
OBJECTIVE: To describe the current status and functioning of robotic programs in Latin-American public hospitals since their beginning to date.
METHODS: We conducted a survey among leading urologists working at public hospitals of Latin-America who had acquired the Da Vinci laparoscopic-assisted robotic system. Questions included: date the program started, its utilization by other services, number and kind of surgeries, surgery paying system, surgery related deaths, occurrence and reasons of robotic program interruptions and its use for training purposes. Medians and 25-75 centiles (IQR) were estimated.
RESULTS: Since 2009, there are ten public hospitals of four Latin-American countries that acquired the Da Vinci robotic system. The median number of months robotic programs has been functioning without considering transitory interruption: 43 (IQR 35, 55). Median number of urologic and total surgeries performed: 140 (IQR 94, 168) and 336 (IQR 292, 621), respectively. The corresponding median number of urologic and total surgeries performed per month: 3 (IQR 2, 5) and 8 (IQR 5, 11). Median number of total surgeries performed per year per institution was 94 (IQR 68,123). The median proportion of urologic cases was 40% (IQR 31, 48), ranging from 24 to 66%. Five of ten institutions had their urology programs transitory or definitively closed due to the high burden costs.
CONCLUSION: Adoption and development of robotic surgery in some public hospitals of Latin-America have been hindered by high costs.

Mesh:

Year:  2018        PMID: 29459996     DOI: 10.1007/s00345-018-2227-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  18 in total

1.  Laparoscopy, robot, telesurgery and urology: future perspective.

Authors:  A K Hemal; M Menon
Journal:  J Postgrad Med       Date:  2002 Jan-Mar       Impact factor: 1.476

2.  New technology and health care costs--the case of robot-assisted surgery.

Authors:  Gabriel I Barbash; Sherry A Glied
Journal:  N Engl J Med       Date:  2010-08-19       Impact factor: 91.245

3.  Cost-Effectiveness of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications.

Authors:  Patricia Marino; Gilles Houvenaeghel; Fabrice Narducci; Agnès Boyer-Chammard; Gwenaël Ferron; Catherine Uzan; Anne-Sophie Bats; Philippe Mathevet; Philippe Dessogne; Frédéric Guyon; Philippe Rouanet; Isabelle Jaffre; Xavier Carcopino; Thomas Perez; Eric Lambaudie
Journal:  Int J Gynecol Cancer       Date:  2015-07       Impact factor: 3.437

Review 4.  Robotic Surgery in Uro-oncology: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Daniel Steffens; Ruban Thanigasalam; Scott Leslie; Bharvi Maneck; Jane M Young; Michael Solomon
Journal:  Urology       Date:  2017-03-20       Impact factor: 2.649

5.  The Australian laparoscopic non robotic radical prostatectomy experience - analysis of 2943 cases (USANZ supplement).

Authors:  Mark William Louie-Johnsun; Marcus M Handmer; Ross John Spero Calopedos; Charles Chabert; Ronald J Cohen; Troy R J Gianduzzo; Paul A Kearns; Daniel A Moon; Jason Ooi; Tom Shannon; David Sofield; Andrew H H Tan
Journal:  BJU Int       Date:  2016-09-23       Impact factor: 5.588

6.  Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study.

Authors:  John W Yaxley; Geoffrey D Coughlin; Suzanne K Chambers; Stefano Occhipinti; Hema Samaratunga; Leah Zajdlewicz; Nigel Dunglison; Rob Carter; Scott Williams; Diane J Payton; Joanna Perry-Keene; Martin F Lavin; Robert A Gardiner
Journal:  Lancet       Date:  2016-07-26       Impact factor: 79.321

Review 7.  Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.

Authors:  Florian Rudolf Schroeck; Bruce L Jacobs; Sam B Bhayani; Paul L Nguyen; David Penson; Jim Hu
Journal:  Eur Urol       Date:  2017-03-31       Impact factor: 20.096

8.  Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy.

Authors:  Vipul R Patel; Ananthakrishnan Sivaraman; Rafael F Coelho; Sanket Chauhan; Kenneth J Palmer; Marcelo A Orvieto; Ignacio Camacho; Geoff Coughlin; Bernardo Rocco
Journal:  Eur Urol       Date:  2011-01-25       Impact factor: 20.096

9.  Overall care cost comparison between robotic and laparoscopic surgery for endometrial and cervical cancer.

Authors:  H Desille-Gbaguidi; T Hebert; J Paternotte-Villemagne; C Gaborit; E Rush; G Body
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2013-09-29       Impact factor: 2.435

10.  A randomised trial of robotic and open prostatectomy in men with localised prostate cancer.

Authors:  Robert A Gardiner; John Yaxley; Geoff Coughlin; Nigel Dunglison; Stefano Occhipinti; Sandra Younie; Rob Carter; Scott Williams; Robyn J Medcraft; Nigel Bennett; Martin F Lavin; Suzanne Kathleen Chambers
Journal:  BMC Cancer       Date:  2012-05-25       Impact factor: 4.430

View more
  2 in total

Review 1.  Colorectal Surgery Practice, Training, and Research in Low-Resource Settings.

Authors:  Kathryn M Chu; Lynn Bust; Tim Forgan
Journal:  Clin Colon Rectal Surg       Date:  2022-09-13

2.  Robot-Assisted Laparoscopic and Thoracoscopic Surgery: Prospective Series of 186 Pediatric Surgeries.

Authors:  Mario Navarrete Arellano; Francisco Garibay González
Journal:  Front Pediatr       Date:  2019-05-21       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.